OTC:AKBLF ALK-Abelló A/S (AKBLF) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free AKBLF Stock Alerts $17.90 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$17.90▼$17.9050-Day Range$17.31▼$18.6552-Week Range$8.20▼$19.90VolumeN/AAverage Volume800 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartHeadlinesStock AnalysisAnalyst ForecastsChartHeadlines Get ALK-Abelló A/S alerts: Email Address Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About ALK-Abelló A/S Stock (OTC:AKBLF)ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food. It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.Read More AKBLF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBLF Stock News HeadlinesApril 24, 2024 | finance.yahoo.comInvitation to the presentation of ALK’s first quarter results on Friday 3 May 2024April 20, 2024 | americanbankingnews.comALK-Abelló A/S (OTC:AKBLF) Trading Down 4%April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.April 18, 2024 | benzinga.comAlaska Air Gr Stock (NYSE:ALK), Quotes and News SummaryMarch 27, 2024 | finance.yahoo.comSave the date for ALK’s Capital Markets Day on 4 June 2024March 14, 2024 | finance.yahoo.comAnnual General Meeting in ALK-Abelló A/S held on 14 March 2024February 16, 2024 | finance.yahoo.comAnnual General Meeting in ALK-Abelló A/S on 14 March 2024February 8, 2024 | finanznachrichten.deALK Abello: Annual report 2023: ALK delivers 9% sales growth with profits up 50%April 26, 2024 | Weiss Ratings (Ad)The Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.February 8, 2024 | finanznachrichten.deALK Abello: ALK and McMaster researchers discover new cell that remembers allergiesFebruary 8, 2024 | finance.yahoo.comAnnual report 2023: ALK delivers 9% sales growth with profits up 50%February 7, 2024 | finance.yahoo.comALK and McMaster researchers discover new cell that remembers allergiesFebruary 5, 2024 | finance.yahoo.comALK’s 2030 CO2 reduction targets have been approved by SBTiJanuary 31, 2024 | finance.yahoo.comRelease date of annual report 2023 for ALK and webcastJanuary 25, 2024 | finance.yahoo.comALK’s European registration application for house dust mite SLIT-tablet in young children accepted for reviewJanuary 18, 2024 | finance.yahoo.comALK completes first part of phase 1 trial with peanut SLIT-tabletJanuary 4, 2024 | finanznachrichten.deALK Abello: ALK to become sole manufacturer and distributor of skin antigen test for penicillin allergyJanuary 4, 2024 | finance.yahoo.comALK to Become Sole Manufacturer and Distributor of Skin Antigen Test for Penicillin AllergyDecember 21, 2023 | uk.investing.comALK-Abello B (0OIR)December 20, 2023 | finance.yahoo.comALK – Financial calendar for the 2024 financial yearDecember 12, 2023 | finanznachrichten.deALK Abello: ALK expands partnership with Torii in JapanDecember 12, 2023 | finance.yahoo.comALK expands partnership with Torii in JapanNovember 15, 2023 | finance.yahoo.comNine-month interim report (Q3) 2023November 9, 2023 | morningstar.comAlk-Abello A/S Class B ALK BNovember 9, 2023 | finance.yahoo.comRelease date of nine-month interim report (Q3) 2023 for ALK and audio castOctober 16, 2023 | finance.yahoo.comALK-Abelló A/S (ALK-B.CO)October 11, 2023 | msn.comALK-Abello: Promising Strides in Tree Pollen Allergy Vaccine for ChildrenSee More Headlines Receive AKBLF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ALK-Abelló A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTC SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTC:AKBLF CUSIPN/A CIKN/A Webwww.alk.net Phone45.45.74.75.76FaxN/AEmployees2,824Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Claus Steensen Solje (Age 52)Executive VP, CFO & Member of Management Board Comp: $2.05MMr. Søren Daniel Niegel (Age 53)Executive VP of Commercial Operations & Member of Management Board Comp: $773.98kDr. Henriette Mersebach (Age 53)Executive VP Research & Development & Member of Management Board Comp: $895.3kMs. Katja Barnkob Thalund (Age 55)Project Director of Global CMC Development & Employee-elected Director Comp: $50.85kMr. Peter Halling (Age 47)President & CEO Mr. Per PlotnikofVP of Corporate Communications, Investor Relations & Strategic Planning and Head of IRProf. Hendrik Kees Kam Nolte M.D.Ph.D., Senior Vice President of Research & Development - North America and International MarketsMr. Christian G. HoughtonHead of Product SupplyMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors AKBLF Stock Analysis - Frequently Asked Questions Should I buy or sell ALK-Abelló A/S stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ALK-Abelló A/S in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKBLF shares. View AKBLF analyst ratings or view top-rated stocks. How have AKBLF shares performed in 2024? ALK-Abelló A/S's stock was trading at $13.25 at the start of the year. Since then, AKBLF stock has increased by 35.1% and is now trading at $17.90. View the best growth stocks for 2024 here. How do I buy shares of ALK-Abelló A/S? Shares of AKBLF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTC:AKBLF) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ALK-Abelló A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
